Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) is positioned at the intersection of artificial intelligence and precision medicine, aiming to transform cardiovascular disease detection. The company's blood-based tests, Epi+Gen CHD and PrecisionCHD, leverage a proprietary AI-driven Multi-Omics Engine that analyzes genetic and epigenetic biomarkers to assess heart attack risk and identify coronary heart disease, including nonobstructive forms often missed by conventional methods. This approach addresses a critical gap in cardiovascular diagnostics, as the disease remains a leading cause of death globally.
The importance of Cardio Diagnostics' technology is underscored by the staggering economic burden of cardiovascular disease. According to the press release, the associated healthcare costs in the U.S. were $393 billion in 2020 and are projected to escalate to $1.4 trillion by 2050. Early detection through advanced testing could significantly reduce these costs by enabling timely interventions. The company has strengthened its commercialization efforts by securing finalized CMS reimbursement rates and dedicated CPT laboratory codes, which facilitate broader adoption among U.S. providers. Additionally, Cardio Diagnostics has launched its first international expansion in India, tapping into a rapidly growing market with high cardiovascular disease prevalence.
The company's AI-driven platform integrates epigenetics and genetics to provide a more comprehensive risk assessment than traditional tools. This precision medicine approach allows for personalized prevention and management strategies. With reimbursement milestones achieved and growing provider partnerships, Cardio Diagnostics occupies a scientifically grounded and commercially actionable position in the diagnostics landscape. For more details, the full article is available at https://nnw.fm/9LJ2r.
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company focused on making cardiovascular disease prevention, detection, and management more accessible and personalized. The company was formed to develop and commercialize clinical tests using its proprietary AI-driven Integrated Genetic-Epigenetic Engine. For more information, visit https://cdio.ai/. The latest news and updates relating to CDIO are available in the company's newsroom at https://nnw.fm/CDIO.
